<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003311</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066258</org_study_id>
    <secondary_id>MDA-DM-97200</secondary_id>
    <secondary_id>NCI-T97-0101</secondary_id>
    <secondary_id>DM97-200</secondary_id>
    <nct_id>NCT00003311</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma</brief_title>
  <official_title>Phase II CCOP Trial of High Dose Methotrexate/ARA-C and HCVAD for Newly Diagnosed Nodular and Diffuse Mantle Cell Lymphoma and Their Blastic Variants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining more than one drug may kill more cancer cells.

      PURPOSE: Phase II trial to study the effectiveness of different regimens of combination
      chemotherapy in treating patients with newly diagnosed mantle cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Evaluate the complete response rate and duration of response in patients with newly
           diagnosed diffuse or nodular mantle cell lymphoma or their blastic variant treated with
           high-dose methotrexate and cytarabine and high-dose cyclophosphamide, dexamethasone,
           doxorubicin, and vincristine (HCVAD).

      OUTLINE: This is a multicenter study. Patients may receive either regimen A or both regimen A
      and regimen B, depending upon response.

        -  Regimen A: Patients receive methotrexate IV over 24 hours on day 1. Cytarabine is
           administered IV over 2 hours every 12 hours on days 2 and 3. Filgrastim (G-CSF) is
           administered subcutaneously (SC) daily beginning on day 4 and continuing until blood
           counts recover. Treatment repeats every 21 days for up to 8 courses.

        -  Regimen B: Patients receive cyclophosphamide IV over 3 hours every 12 hours on days 1-3.
           Doxorubicin is administered IV over 24 hours on days 4 and 5. Vincristine is
           administered IV over 30 minutes on days 4 and 11. Dexamethasone is administered orally
           or IV on days 1-4 and 11-14. G-CSF is administered SC beginning on day 6 and continuing
           until blood counts recover. Treatment repeats every 21 days for up to 7 courses.

      Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months
      for 2 years, and then annually thereafter.

      PROJECTED ACCRUAL: A total of 21-45 patients will be accrued for this study within 4 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1999</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate IV over 24 hours on day 1. Cytarabine is administered IV over 2 hours every 12 hours on days 2 and 3. Filgrastim (G-CSF) is administered subcutaneously (SC) daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for up to 8 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide IV over 3 hours every 12 hours on days 1-3. Doxorubicin is administered IV over 24 hours on days 4 and 5. Vincristine is administered IV over 30 minutes on days 4 and 11. Dexamethasone is administered orally or IV on days 1-4 and 11-14. G-CSF is administered SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for up to 7 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_label>Regimen B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Regimen B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <arm_group_label>Regimen B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Regimen B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>Regimen A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Regimen B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed previously untreated nodular or diffuse mantle cell lymphoma
             or their blastic variant

          -  No CNS involvement

          -  Not a candidate for stem cell transplantation or refuses one

        PATIENT CHARACTERISTICS:

        Age:

          -  16 and over

        Performance status:

          -  Zubrod 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count greater than 1,000/mm^3*

          -  Platelet count greater than 100,000/mm^3* NOTE: * Unless lymphoma involvement

        Hepatic:

          -  Bilirubin less than 1.5 mg/dL (unless lymphoma involvement)

        Renal:

          -  Creatinine less than 2.0 mg/dL (unless lymphoma involvement)

        Cardiovascular:

          -  Cardiac ejection fraction at least 50% (for patients over age 40)

        Other:

          -  Must be willing to receive blood transfusion

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No other co-morbid medical or psychiatric illness that would preclude treatment

          -  No prior or concurrent malignancy with poor prognosis (less than 90% probability of
             survival at 5 years)

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  See Disease Characteristics

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge E. Romaguera, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 24, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2003</study_first_posted>
  <last_update_submitted>October 5, 2012</last_update_submitted>
  <last_update_submitted_qc>October 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

